Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance

Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.30), $0.19 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $183.28 million.

GUIDANCE:

Corcept Therapeutics sees FY2026 revenue of $0.95-1.05 billion, versus the consensus of $0.93 billion.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Tesla To Hire 1,000 More Workers At Plant Outside Berlin - DPA
• Mistras Group expands Houston lab for aerospace and defense work